Maternal and perinatal outcomes in pregnant women with rheumatic diseases treated with biosimilar TNF inhibitors

Rheumatol Adv Pract. 2024 Mar 19;8(2):rkae044. doi: 10.1093/rap/rkae044. eCollection 2024.

Ana Teodósio Chícharo^{1

2}, Ana R Lopes^{1

3}, Sofia Barreira^{1

3}, Luísa Pinto⁴, Ana R Cruz-Machado^{1

3}, Susana Capela^{1

3}

¹ Rheumatology and Metabolic Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Center, European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET) and RITA Full Member, Lisbon, Portugal.
² Rheumatology Department, Centro Hospitalar Universitário do Algarve, Hospital de Faro, Faro, Portugal.
³ Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.
⁴ Department of Obstetrics, Gynecology and Reproductive Medicine, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.

No abstract available